These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 34076909)

  • 21. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis.
    Novitzky N; Thomas V; du Toit C; McDonald A
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):875-84. PubMed ID: 20870030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1.
    Bourlon C; Lipton JH; Deotare U; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Thyagu S; Messner HA; Michelis FV
    Eur J Haematol; 2017 Sep; 99(3):234-239. PubMed ID: 28556258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
    Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
    Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia.
    Ustun C; Courville EL; DeFor T; Dolan M; Randall N; Yohe S; Bejanyan N; Warlick E; Brunstein C; Weisdorf DJ; Linden MA
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):669-675. PubMed ID: 26551635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.
    Malard F; Labopin M; Cho C; Blaise D; Papadopoulos EB; Passweg J; O'Reilly R; Forcade E; Maloy M; Volin L; Castro-Malaspina H; Hicheri Y; Jakubowski AA; Orvain C; Giralt S; Mohty M; Nagler A; Perales MA
    J Hematol Oncol; 2018 Oct; 11(1):127. PubMed ID: 30342553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.
    Vu K; Manjappa S; DiPersio JF; Gao F; Westervelt P; Vij R; Stockerl-Goldstein KE; Uy GL; Abboud CN; Schroeder MA; Fehniger TA; Cashen AF; Romee R
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1425-30. PubMed ID: 25840336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
    Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
    Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia.
    Ciftciler R; Demiroglu H; Buyukasık Y; Aksu S; Goker H
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e205-e212. PubMed ID: 30665867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
    Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
    Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.
    Nagler A; Dholaria B; Labopin M; Socie G; Huynh A; Itälä-Remes M; Deconinck E; Yakoub-Agha I; Cahn JY; Bourhis JH; Labussière-Wallet H; Chantepie S; Esteve J; Savani B; Mohty M
    Leukemia; 2020 Apr; 34(4):1144-1153. PubMed ID: 31728052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC).
    Pochon C; Detrait M; Dalle JH; Michel G; Dhédin N; Chalandon Y; Brissot E; Forcade E; Sirvent A; Izzadifar-Legrand F; Michallet M; Renard C; Yakoub-Agha I; Gonzales F; Bay JO; Kanold J; Cornillon J; Bulabois CE; Angoso M; Nguyen S; Balza M; Chevallier P; Rialland F; Bazarbachi A; Beguin Y; Huynh A; Ménard AL; Schneider P; Neven B; Paillard C; Raus N; Albuisson E; Remen T; Rubio MT
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2083-2097. PubMed ID: 34480598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
    Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant.
    Thoma MD; Huneke TJ; DeCook LJ; Johnson ND; Wiegand RA; Litzow MR; Hogan WJ; Porrata LF; Holtan SG
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):600-7. PubMed ID: 21843495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.